Immunity to poliomyelitis in The Netherlands
- PMID: 11157405
- DOI: 10.1093/aje/153.3.207
Immunity to poliomyelitis in The Netherlands
Abstract
Despite a vaccination coverage rate of 97%, several poliomyelitis outbreaks occurred in the Netherlands during the last three decades, all among sociogeographically clustered, unvaccinated persons. Therefore, to eradicate polio, insight into poliomyelitis immunity is particularly useful. In 1995-1996, the authors conducted a population-based study and determined neutralizing antibodies against poliovirus types 1, 2, and 3 in 9,274 sera from the general population and from religious groups rejecting vaccination. In the general population, the antibody prevalence (>/=1:8) was 96.6% (95% confidence interval (CI): 95.9, 97.2), 93.4% (95% CI: 92.3, 94.5), and 89.7% (95% CI: 88.3, 91.0) for poliovirus types 1, 2, and 3, respectively. Antibodies persisted for long periods in persons with natural immunity as well as in persons whose immunity was induced by inactivated polio vaccine. In Orthodox Reformed persons, the antibody prevalence of poliovirus types 1, 2, and 3 was 65.0% (95% CI: 57.2, 72.9), 59.0% (95% CI: 40.1, 77.9), and 68.7% (95% CI: 65.2, 72.2), respectively. The recent outbreaks clearly affected the seroprevalence profiles of Orthodox Reformed groups but not the general population. At present, there is an insufficient social and political basis for mandatory vaccination; therefore, global eradication of poliovirus seems to be the only way to protect these Orthodox Reformed persons against future poliomyelitis outbreaks.
Comment in
-
Invited commentary: stopping polio immunization.Am J Epidemiol. 2001 Feb 1;153(3):215-6; discussion 217-8. doi: 10.1093/aje/153.3.215. Am J Epidemiol. 2001. PMID: 11157406 No abstract available.
-
Re: "Immunity to poliomyelitis in the Netherlands".Am J Epidemiol. 2001 Oct 1;154(7):684-5. doi: 10.1093/aje/154.7.684. Am J Epidemiol. 2001. PMID: 11581104 No abstract available.
Similar articles
-
Poliovirus circulation among schoolchildren during the early phase of the 1992-1993 poliomyelitis outbreak in The Netherlands.J Infect Dis. 2001 Dec 1;184(11):1451-5. doi: 10.1086/324327. Epub 2001 Nov 13. J Infect Dis. 2001. PMID: 11709788
-
Immunity against poliomyelitis in the Netherlands, assessed in 2006 to 2007: the importance of completing a vaccination series.Euro Surveill. 2014 Feb 20;19(7):20705. doi: 10.2807/1560-7917.es2014.19.7.20705. Euro Surveill. 2014. PMID: 24576472
-
A seroprevalence study of poliovirus antibody in the population of northern Greece.Clin Microbiol Infect. 2005 Jan;11(1):68-71. doi: 10.1111/j.1469-0691.2004.00998.x. Clin Microbiol Infect. 2005. PMID: 15649308
-
Vaccination against polio should not be stopped.Nat Rev Microbiol. 2007 Dec;5(12):952-8. doi: 10.1038/nrmicro1769. Nat Rev Microbiol. 2007. PMID: 17965726 Review.
-
[Poliomyelitis in The Netherlands, 1979-1991: immunity and exposure].Ned Tijdschr Geneeskd. 1993 Jul 10;137(28):1380-6. Ned Tijdschr Geneeskd. 1993. PMID: 8240513 Review. Dutch.
Cited by
-
Feasibility of quantitative environmental surveillance in poliovirus eradication strategies.Appl Environ Microbiol. 2012 Jun;78(11):3800-5. doi: 10.1128/AEM.07972-11. Epub 2012 Mar 23. Appl Environ Microbiol. 2012. PMID: 22447593 Free PMC article.
-
Global lessons from India's poliomyelitis elimination campaign.Bull World Health Organ. 2010 Mar;88(3):232-4. doi: 10.2471/BLT.09.072058. Bull World Health Organ. 2010. PMID: 20428393 Free PMC article. No abstract available.
-
Is EU/EEA population protected from polio?Hum Vaccin Immunother. 2015;11(9):2123-31. doi: 10.1080/21645515.2015.1016673. Epub 2015 Apr 21. Hum Vaccin Immunother. 2015. PMID: 25898095 Free PMC article.
-
Seroprevalence of antipolio antibodies among children <15 years of age in border provinces in China.Clin Vaccine Immunol. 2013 Jul;20(7):1070-5. doi: 10.1128/CVI.00092-13. Epub 2013 May 15. Clin Vaccine Immunol. 2013. PMID: 23677325 Free PMC article.
-
Sero-survey of polio antibodies during wild poliovirus outbreak in southern Xinjiang Uygur Autonomous Region, China.PLoS One. 2014 Jul 3;9(7):e80069. doi: 10.1371/journal.pone.0080069. eCollection 2014. PLoS One. 2014. PMID: 24991811 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical